PERSISTENCE TO DENOSUMAB IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AT INCREASED FRACTURE RISK TREATED IN ROUTINE CLINICAL PRACTICE IN BULGARIA

被引：0
|
作者：
Monov, S. [1 ]
Nestorova, R. [2 ]
Velkova, M. [3 ]
Temelkova, N. [4 ]
Jeleva, S. [5 ]
Petkova, R. [6 ]
Petranova, T. [1 ]
机构：
[1] Med Univ, Clin Rheumatol, Sofia, Bulgaria
[2] ASIMP RC St Irina, Sofia, Bulgaria
[3] ASIMP Rheumatol, Russe, Bulgaria
[4] Univ Hosp Alexandrovska, Sofia, Bulgaria
[5] Med Ctr Orfey, St Zagora, Bulgaria
[6] Amgen Bulgaria, Sofia, Bulgaria
来源：
OSTEOPOROSIS INTERNATIONAL | 2020年 / 31卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P856
引用
收藏
页码：S442 / S443
页数：2
相关论文
共 50 条
  • [1] INCREASED BONE MINERAL DENSITY (BMD) IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS (OP) RECEIVING TWO DENOSUMAB INJECTIONS IN ROUTINE CLINICAL PRACTICE IN BULGARIA
    Boyanov, M.
    Shinkov, A.
    Psachoulia, E.
    Intorcia, M.
    Petkova, R.
    VALUE IN HEALTH, 2014, 17 (07) : A389 - A389
  • [2] INCREASED BONE MINERAL DENSITY (BMD) IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS (OP) RECEIVING TWO DENOSUMAB INJECTIONS IN ROUTINE CLINICAL PRACTICE IN BULGARIA
    Boyanov, M.
    Shinkov, A.
    Psachoulia, E.
    Intorcia, M.
    Petkova, R.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S84 - S84
  • [3] Persistence with Denosumab in Women at High Risk of Fracture in Bulgaria
    Simeon Monov
    Rodina Nestorova
    Margarita Velkova
    Mihail Boyanov
    Silvia Jeleva
    Renata Petkova
    Tzvetanka Petranova
    Rheumatology and Therapy, 2021, 8 : 443 - 455
  • [4] Persistence with Denosumab in Women at High Risk of Fracture in Bulgaria
    Monov, Simeon
    Nestorova, Rodina
    Velkova, Margarita
    Boyanov, Mihail
    Jeleva, Silvia
    Petkova, Renata
    Petranova, Tzvetanka
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 443 - 455
  • [5] CHARACTERISTICS OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS INITIATING DENOSUMAB IN BULGARIA
    Boyanov, M.
    Shinkov, A.
    Psachoulia, E.
    Intorcia, M.
    Petkova, R.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S190 - S190
  • [6] Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis
    Palacios, S.
    Kalouche-Khalil, L.
    Rizzoli, R.
    Zapalowski, C.
    Resch, H.
    Adachi, J. D.
    Gallagher, J. C.
    Feldman, R. G.
    Kendler, D. L.
    Wang, A.
    Wagman, R. B.
    Adami, S.
    CLIMACTERIC, 2015, 18 (06) : 805 - 812
  • [7] BONE MARKERS IN POSTMENOPAUSAL WOMEN: EVALUATION OF OSTEOPOROSIS RISK INDEX IN WOMEN TREATED WITH DENOSUMAB
    Kocevska, A. K.
    Todorova, B. J. T. Jovanoska
    Nakov, A. N.
    Kocevska, B. K.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S321 - S321
  • [8] Clinical evaluation of osteoporosis and fracture risk in postmenopausal women
    McClung B.
    Clinical Reviews in Bone and Mineral Metabolism, 2006, 4 (1): : 15 - 23
  • [9] DENOSUMAB PERSISTENCE IN POSTMENOPAUSAL AND MALE OSTEOPOROSIS IN ROUTINE CLINICAL PRACTICE IN HUNGARY: A NATIONAL, SINGLE-ARM, PROSPECTIVE OBSERVATIONAL STUDY
    Gaal, J.
    Valkusz, Z.
    Kudlak, K.
    Balogh, I.
    Molnar, E.
    Takacs, I.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S134 - S135
  • [10] Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab
    Toulis, K. A.
    Anastasilakis, A. D.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (11) : 1963 - 1964
12345